Methotrexate's mechanism of action aects both the in¯ammatory and immunosuppressive aspects of response. Its kinetics are de®ned and include variable absorption, intracellular metabolism, and both renal and biliary excretion. Methotrexate is clearly eective in the treatment of rheumatoid arthritis and may be able to decrease the rate of formation of new bony erosions. It is also eective in psoriatic arthritis and is being used in a multiplicity of other rheumatic diseases. The most common toxicities ascribed to methotrexate are gastrointestinal (e.g. stomatitis) and central nervous system (e.g. headache, fatigue, malaise). Methotrexate-induced hepatic cirrhosis is less common in rheumatoid arthritis than previously thought, although its occurrence in psoriasis is probably higher than in rheumatoid arthritis. Haematological, renal and pulmonary toxicity occur, but are rare, while teratogenicity is well documented. A new and disturbing adverse event, pseudolymphomas are being reported at present.
MTX also accumulates in bone marrow precursors and gastrointestinal cell precursors, one would expect these cells to be vulnerable to MTX toxicity [11] .
Although the ratio of synovial¯uid to plasma concentrations approximates one, synovial membrane and bone concentrations are H10 times plasma concentrations [5, 12] . Despite this, plasma kinetics appear unaltered, making it unlikely that intra-articular MTX will yield an advantage over systemic therapy [12, 13] .
Summary. An understanding of MTX's distribution and metabolism can help guide rational therapy with this drug. CLEARANCE MTX clearance decreases by a factor of approximately three as age increases from 7 to 15 yr, explaining why some children require larger doses than adults [14] . Further, both renal and metabolic MTX clearance decrease at night (by 50 and 14%, respectively), at least in children, supplying a rationale for changes in response (either ecacy or toxicity) with changes in dosing regimens [15] .
The elimination half-life of MTX approximates 7 h, although some patients (17% in one study) have half-lives as long as 26 h [5] . Total MTX clearance is 80±90 ml/min/m 2 , with renal tubular mechanisms playing the major role in MTX elimination [16, 17] . Since renal clearance is MTX's principal route of elimination, patients with renal failure should exhibit decreased overall MTX clearance. Compared with a mean renal clearance of 84.6 ml/min/m 2 in normal RA patients, renal clearance was 2.8 ml/min/m 2 in patients with severely impaired renal function [5, 18] . Since MTX has low protein binding and high tissue distribution, haemodialysis or peritoneal dialysis would not be a very eective way to clear the drug [18] . On the other hand, biliary excretion may account for up to 30% of MTX excretion, thus giving patients with renal failure a`safety valve' in which increasing biliary excretion may help compensate for decreasing renal excretion [19] . Furthermore, the biliary excretory route can be utilized to increase MTX blood clearance by using cholestyramine [20] . In contrast, probenecid can increase the MTX area under the plasma concentration vs time curve (AUC) by 25% in oncological doses [21] . Since neither the cholestyramine nor the probenecid interactions have been tested in RA patients, this information needs to be used with some care.
MTX±non-steroidal anti-in¯ammatory drug (NSAID) interactions have generated both signi®cant interest and some controversy. Kinetically, aspirin consistently decreases both total and renal MTX clearance [22] . In contrast, no signi®cant changes in MTX kinetics has been documented after etodolac, urbiprofen or naproxen (despite some controversy with respect to naproxen) [22] . Ibuprofen has been associated with both increased MTX clearance and unchanged MTX clearance, while sulindac has aected metabolic but not renal clearance of MTX [22] .
Clinically, many NSAIDs have been associated with case reports of clinically important adverse events after MTX [22] . These include: leucopenia after aspirin; gastrointestinal (GI) toxicity after azapropazone, indomethacin and naproxen; bone marrow hypoplasia or aplasia after diclofenac, ketoprofen and azapropazone; and renal failure after diclofenac, indomethacin and ketoprofen [22] . However, these interactions must be rare as Rooney et al. [23] found no dierence in toxicity among 12 patients treated with MTX and aspirin as compared to 22 patients treated with MTX and other NSAIDs over 12 months. Although rare, serious NSAID± MTX adverse events can occur with any NSAID, including aspirin.
Summary
(a) Since renal clearance is the principal mechanism of MTX excretion, the use of MTX in renal insuciency is hazardous, although not impossible. (b) Since bile may, occasionally, account for a signi®cant portion of MTX excretion, this pathway can be exploited to decrease MTX blood concentrations in the case of overdose, by using cholestyramine. (c) In contrast, probenecid, which inhibits both renal and biliary excretory pathways, may be a way to improve the cost-eective use of MTX, although this has not been formally tested. (d) Clinically important toxicities from aspirin and NSAID eects on MTX are rare, are not dierent for aspirin vs other NSAIDs, and are not well re¯ected by kinetic studies.
Other interactions
There have been at least seven documented cases of pancytopenia or other bone marrow suppression after the combined use of MTX and trimethoprim± sulphamethoxazole or trimethoprim [22, 23] . The mechanism of this rare interaction is not well understood.
Likewise, a potential interaction between MTX and corticosteroids indicates that patients on longterm corticosteroids may have as much as a 20% decrease in MTX clearance, accompanied by a 24% decrease in renal clearance [24] . This potentially interesting interaction has been documented in a study of somewhat unconventional design and will need corroboration.
While the addition of hydroxychloroquine to MTX results in fewer aspartate aminotransferase elevations in an observational study, this has not yet been corroborated in a prospective controlled study and it is also not clear that decreasing the frequency or degree of AST elevations is protective against cirrhosis [25] .
A positive interaction between folic acid and MTX shows that the addition of 1 mg/day folic acid decreases MTX-induced toxicity, particularly with respect to stomatitis, and GI side-eects [25±27].
Summary
Practically, these data indicate that one should be somewhat more careful when using trimethoprim±sul-phamethoxazole combinations or trimethoprim in MTX-treated patients with urinary tract infections, and that folic acid can (and perhaps should) be used frequently to decrease MTX toxicity. The data on corticosteroid eects are not strong enough, in my view, to warrant a change in therapy and the use of hydroxychloroquine with MTX to decrease AST elevations is common, although its verity and long-term eectiveness are not proven. [30] was a 13 week cross-over study examining i.m. rather than oral MTX. The patients treated with placebo had more swollen joints than the MTX group at baseline (26 vs 16), but the 9.1 mean swollen joint count decrease in the MTX group was statistically more than the 6.6 mean swollen joint count decrease among the placebo-treated patients. The mean change in erythrocyte sedimentation rate (ESR) was also more (24 mm in the MTX group vs 3 mm in the placebo-treated patients). The study of Furst et al. [32] had a parallel design and showed a dose-related eect, with 5 and 10 mm/m 2 being more eective in general than placebo. However, this study included a 12 day hospitalization during which all patients improved. Response was related to this improved post-hospitalization point, so placebo patients worsened (and returned to pre-hospitalization activity) while others remained stable (5 mg/m 2 ) or improved further (10 mg/m 2 ). The major eect occurred at 10 mg/m 2 (an average of H17.5 mg/week) where a >50% improvement occurred in 6/11 measures. A dose response was demonstrated for 5±11 ecacy measures and for GI toxicity. Forty-eight patients in the study of Thompson et al. [31] used i.m. MTX (10 or 25 mg) vs i.m. placebo for only 6 weeks followed by collapse of the placebo patients into one of the active treatment arms for another 6 weeks. In essence, this was a cross-over trial, from placebo to either 10 or 25 mg MTX in H16 patients. It showed improvement relative to placebo in all indices. The Weinblatt et al. study [29] was a crossover study using oral MTX and allowing dose escalation from 7.5 to 15 mg a week. Joint swelling count among the MTX-treated patients improved more than placebo, whereas there was no dierence between drug and placebo for joint tenderness. The study of Williams et al. [28] was by far the largest, comprising 189 patients. It was performed early in the use of MTX and required discontinuations of drug for mild elevations in liver function tests. Hence, 80 patients discontinued the drug, partially mitigating its size. Thirty-one per cent of patients discontinued MTX secondary to`drug toxicity' as compared to 11% on placebo. In contrast, 21% of placebo patients discontinued the study secondary to inecacy compared to only 3% of MTX-treated patients.
EFFICACY

Placebo-controlled studies
The meta-analysis of Tugwell et al. [33] demonstrated a 26±39% improved joint tenderness count and pain visual analogue scale (VAS), and 27% decreases in joint swelling counts and ESR compared to placebo.
Positively controlled and combination trials
Six double-blind positively controlled trials used MTX (Table II) and another ®ve trials used MTX in combination (Table III) [35±44]. Three trials compared MTX vs gold sodium thiomalate (GST) [35, 37, 38] . Morassut et al. [38] used p.o. MTX (12.5 mg weekly) vs i.m. GST over 26 weeks. In general, the GST and MTX were equally eective and equally toxic, although there were sometimes trends for GST to improve more than MTX. For example, all nine ecacy measures improved statistically after GST, while seven of nine improved on MTX. The authors rightfully pointed out that the power to tell dierences between treatments was small (there were only 17 patients on GST and 18 patients on MTX), so they declared the treatments equal. Six patients discontinued gold secondary to toxicity and three dis- MTX patients discontinued secondary to inecacy compared to 13 patients taking aurano®n (P = 0.047) and 7% of MTX patients discontinued therapy secondary to toxicity compared to 22% of the aurano®n group (P < 0.01). Williams et al. [40] , as part of a combination therapy trial (Table III) , also compared MTX to aurano®n. In their large trial, however, a ®xed dose of aurano®n (6 mg) and a low ®xed dose of MTX (7.5 mg weekly) were compared. In that trial, the aurano®n and MTX treatment showed equal ecacy. Three trials compared azathioprine with MTX, one of those being part of a combination therapy study [34, 39, 41] . Hamdy et al. [39] only examined a very small group of patients, but commented that all nine ecacy parameters improved in both groups with a trend (not statistically signi®cant) toward more rapid and greater improvement in the MTX-treated patients. Jeurissen et al.'s [34] 48 week trial showed that 12/13 ecacy measures improved in the MTXtreated group, while 6/13 measures improved statistically in the azathioprine-treated patients. In those patients who completed the trial, response was equivalent, but 64% of the patients discontinued azathioprine, while only 19% discontinued MTX. Overall, Jeurissen et al. felt that MTX was more eective than azathioprine. The third comparison between MTX and azathioprine was part of a combination therapy study in which Willkens et al. [41] compared azathioprine 50±150 mg a day and MTX 5±15 mg a week, to 5±7.5 mg MTX plus 50±100 mg azathioprine over 24 weeks. Willkens et al. used a >30% response in three of four ecacy variables as a combined response measure. Forty-four per cent of the azathioprine-treated patients improved by this amount, while 55% of the MTX-treated patients did the same. At 12 weeks, the MTX-treated group was statistically better than the azathioprine group, but this dierence was gone by 24 weeks because, essentially, the azathioprine-treated patients were`responder enriched'. This is because a large number of azathioprine-treated patients discontinued the trial (38%) compared to only 7% discontinuing MTX. This implies that responders remained in the trial for the full 24 weeks, decreasing any dierences that might have occurred early. The azathioprine-treated patients also experienced more toxicity than did the MTX group. Among the ®ve combination therapy trials, only two utilized a`classical' design comparing each drug separately to their combination [40, 41] . The other three trials (see below) utilized less conventional designs (Table III) [42±44].
In Willkens et al.'s study [41] , a lower dose combination of MTX and azathioprine was compared to more usual and higher doses of each drug alone. The combination therapy fared as well as, but no better than, the MTX-alone group and better than the azathioprine-treated patients (58% vs 55% vs 44% response; see Table III ). MTX alone was equally eective and no more toxic than the combination. Williams et al. [40] compared usual doses of aurano®n, a low dose of MTX (7.5 mg a week), and their combination, in over 100 patients per group. All treatment regimens were equally eective even though a low dose of MTX was used. When examining discontinuations secondary to inecacy on the other hand, MTX discontinuations (7%) and combination therapy discontinuations (2%) were equal and fewer than discontinuations among the aurano®n-treated patients (13%) (P = 0.004). Tugwell et al. [42] employed a dierent design, utilizing patients who had`failed' MTX secondary to continued disease activity at maximum tolerated dose (mean 12.5 mg/ week). While continuing the MTX, cyclosporin at a mean ®nal dose of 2.97 mg/kg/day or placebo was added. Sixteen per cent of the MTX plus placebotreated patients improved by ACR improvement criteria, while 48% of the patients utilizing MTX plus cyclosporin improved by this combined measure (P < 0.001). Toxicity was also generally equal, although the serum creatinine increased more in the combination-treated group than the placebo-treated patients (0.14 mg/dl vs 0.05 mg/dl; P < 0.02). Ferraz et al. [43] compared low-dose MTX (7.5 mg weekly) to MTX (7.5 mg/week) and chloroquine (250 mg/ day). The analysis examined only those patients who completed the trial. Three of the seven ecacy measures favoured the combination, while the other four did not, despite the low-dose MTX. Interestingly, 12 patients utilizing the combination experienced elevations of hepatic enzymes vs seven on MTX alone. O'Dell et al. [44] compared MTX to hydroxychloroquine plus sulphasalazine (HCQ/SSZ) to all three together. In 31±36 patients per group followed for 2 yr the well-de®ned response rate was 33% in the MTX group, 40% in the HCQ/SSZ-treated patients and 77% in the triple-combination group. The triple combination was clearly more eective, while the other two treatments were equivalent.
An interesting meta-analysis by Felson et al. [46] examined combination therapies in RA. They utilized a methodology which allowed two-way con®dence intervals to be constructed so that comparisons could be made visually in two axes. In general, combination trials resulted in a marginal improvement over monotherapy in tender joint count (4%; P < 0.001) and no improvement in swollen joint count (1.7%; P = 0.008).
Observational studies indicate that more patients remain on MTX after 3 yr than other DMARDs [47] . Between 45 and 62% of patients remained on MTX after 3 yr compared to 18±62% on i.m. gold, 35% on hydroxychloroquine, and 11±39% on sulphasalazine.
Radiographic progression
Four studies, each small or with signi®cant weaknesses, support the concept that MTX retards new bony damage in RA [45, 48] . In contrast, two studies, with similar weaknesses, do not do so [36] . Using individual patient data from these studies, a metaanalysis persuasively showed that MTX slowed the appearance of new erosions more eectively than azathioprine and as eectively as i.m. gold [49] .
Summary. MTX is eective for treating RA and it may slow the appearance of new erosions.
O indication use
Controlled studies. Two well-controlled, blinded studies used MTX to treat psoriatic arthritis [50, 51] . In one, 21 hospitalized patients were given 1±3 mg/kg MTX every 10 days for 30 days compared to placebo. Patients given MTX had more improvement in joints and skin than did the placebo group [50] . In the other study, 37 patients responded to 7.5±15 mg weekly MTX orally better with respect to physician global and skin involvement, but did not separate MTX from placebo with respect to joint tenderness or swelling [51] . Double-blind, placebo-controlled studies of juvenile chronic arthritis (JCA) (also called juvenile RA) chronically suer from a large placebo response. The use of MTX in JCA was no exception for it took three trials and a meta-analysis involving 127 children to separate 10 mg/week MTX from placebo [52] . In this case, 63% of the MTX-treated children responded, using a combined index, compared to 36% of placebo-treated patients.
Uncontrolled studies. MTX has been successfully utilized in uncontrolled studies of patients with systemic lupus erythematosus, in¯ammatory bowel disease, ankylosing spondylitis, temporal arteritis, Wegener's granulomatosis, and systemic sclerosis [53± 57]. One short controlled trial in systemic sclerosis was unsuccessful [58] . As usual, open studies are encouraging, but one must await well-controlled, blinded studies, some of which are presently being undertaken, to sort out the true place of MTX in the treatment of these diseases. Table IV outlines the range of MTX's toxicities found in the medical literature.
TOXICITY
Gastrointestinal toxicity including stomatatitis, nausea and abdominal distress is most common [59, 60] .
Central nervous system eects, including headache, fatigue, and malaise, are surprisingly common, but are frequently not volunteered. They occurred in up to 67% in one study [59±61] .
Cirrhosis may occur, although its incidence is controversial [62, 63] . An ACR ad hoc committee recommended liver biopsies only after 5 yr or if liver function tests were frequently elevated [63] . Baseline CBC, liver function tests and serological tests for hepatitis B and C are recommended. Follow-ups are useful, with CBCs and liver function tests every 2±4 weeks initially and then every 4±8 weeks; serum creatinines should be done every 4±12 weeks [62, 63] . An analysis of the cost eectiveness of liver biopsy in MTX-treated patients with RA has been published [62] . Its claim that liver biopsies are not cost eective after 5 yr of treatment is based on an assumption that cirrhosis occurs in 1 out of 1000 cases. Unfortunately, some studies indicate more frequent cirrhosis (up to 3%), so that this article must be considered as somewhat speculative [63] .
Haematological side-eects do occur, including occasional leucopenia and rare thrombocytopenia, although they are not a principal area of concern when using MTX (Table I) [61, 64] . Similarly, renal toxicity can occur, but is quite rare.
MTX interactions with NSAIDs raise some concern. These most frequently result in mild diminution in creatinine clearance and are extremely rare causes of clinical toxicity. No great dierence exists between aspirin and other NSAIDs with respect to renal toxicity [22, 23, 48, 64] .
Pulmonary hypersensitivity associated with severe hypoxaemia occurs in 1±7% of patients given MTX [59, 60, 64] . Thus far, it has usually been reversible, but is unpredictable. Recurrent pulmonary disease after re-treatment with MTX has been reported.
Teratogenicity is well documented after MTX and MTX has been used in combination with misoprostol as an abortifacient [65, 66] .
Pseudolymphomas continue to be reported after MTX use (J. M. S. Davies, personal communication). The name pseudolymphoma comes from the appearance of the pathology which looks like a large cell lymphoma, but this lesion disappears when MTX is withdrawn (J. M. S. Davies, personal communication). Of course, the lymphoma is usually treated, but spontaneous large cell lymphoma usually recurs, while it does not recur after MTX withdrawal.
Opportunistic infections have repeatedly been reported after MTX use, including infection with Pneumocystis carinii, aspergillosis, cryptococcosis, nocardiosis and herpes zoster [67±70] . The issue of whether MTX increases the incidence of bacterial infections in RA patients remains controversial [70] . While anaphylactic reactions have been reported to the Food and Drug Administration (FDA), only 5/24 reported cases were in patients with rheumatic diseases (two with JRA, one with polymyositis and two with RA) (FDA inquiry). In two cases, the patients were re-challenged without recurrence of symptoms. In the other three cases, no re-challenge was undertaken. The other 19 cases of anaphylaxis were in patients given MTX for malignancies.
Summary
MTX causes discontinuation of therapy less than other DMARDs. GI and central nervous system toxicities are most common, while rare pneumonitis and cirrhosis are most serious. The issues of pseudolymphoma and a tendency towards increased infections when using MTX are not yet settled.
